GNA Biosolutions Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • GNA Biosolutions's estimated annual revenue is currently $3.7M per year.(i)
  • GNA Biosolutions's estimated revenue per employee is $155,000

Employee Data

  • GNA Biosolutions has 24 Employees.(i)
  • GNA Biosolutions grew their employee count by -37% last year.

GNA Biosolutions's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is GNA Biosolutions?

GNA Biosolutions is a private molecular diagnostics company located in Germany. Our proprietary technology, Pulse Controlled Amplification (PCA), offers a novel, ultrafast, and cost-effective molecular diagnostic platform that captures and amplifies nucleic acids from complex clinical samples. PCA assays are being developed for a number of therapeutic areas, including infectious diseases and biothreats. Nucleic acid amplification is a fundamental process in molecular biology, with a multitude of applications. In collaboration with our partners around the world, our PCA technology is taking molecular testing to places it's never been able to go before. Our vision is to bring the power of molecular testing, from sample to answer, to everyone, everywhere. For more information, please visit www.gna-bio.com

keywords:N/A

N/A

Total Funding

24

Number of Employees

$3.7M

Revenue (est)

-37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

GNA Biosolutions News

2022-04-20 - life Science Instruments and Reagents Market 2021 to 2030 ...

GNA Biosolutions GmbH had launched Pharos V8 ? the world's first Laser PCR platform. Another example is the launch of new INVENIO Fourier Transform...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.1M2426%N/A
#2
$3.7M24-14%N/A
#3
$2.9M24-14%N/A
#4
$3.7M254%N/A
#5
$2.5M25N/AN/A